Maarten Lambrecht retweeted
S1914: Adding immunotherapy to SBRT did NOT improve outcomes in early-stage NSCLC 🚫
Phase III SWOG/NRG S1914
High-risk, early-stage, medically inoperable NSCLC
402 eligible patients
• Atezolizumab + SBRT: 201
• SBRT alone: 201
• Atezolizumab 1200 mg q3w, up to 8 cycles
• SBRT started with cycle 3
📊 Updated efficacy
2-year PFS
• Atezo + SBRT: 66%
• SBRT: 67%
• HR 0.93 (95% CI 0.66–1.31)
2-year OS
• Atezo + SBRT: 82%
• SBRT: 82%
• HR 1.04 (95% CI 0.69–1.58)
⚠️ More toxicity
Grade ≥3 treatment-related AEs:
• Atezo + SBRT: 12%
• SBRT: 3%
Two grade 5 respiratory events occurred with atezolizumab + SBRT.
The trial closed early for futility.
🔑 Take-home:
For unselected patients with early-stage inoperable NSCLC, adding peri-SBRT atezolizumab increased toxicity without improving PFS or OS.
SBRT alone remains the standard of care.
@SWOG @NRGonc @TheLancetOncol @oncoalert
#LCSM #NSCLC #RadiationOncology #Immunotherapy
Maarten Lambrecht retweeted
Placebo Controlled Randomized Trial: Memantine given w/Brain RT Improved Cognitive Outcomes & QOL 1/3 sciencedirect.com/science/ar…
Maarten Lambrecht retweeted
Cognition sparing SRS compared to N0574/N107C SRS
COG-SRS better all-domains cognitive outcomes, especially language
#ASTRO26 abstract #280 sciencedirect.com/science/ar…
Maarten Lambrecht retweeted
Great @EANOassociation @ESTRO_RT #Roma2026 session on cognitive-sparing radiotherapy chaired by Jona Hattangadi-Gluth and Anthony Chalmers. Thanks to all the speakers for their outstanding talks and discussion! #EANO2026
Maarten Lambrecht retweeted
Radiotherapy after surgery halves risk of recurrence in a type of brain tumour that can often grow back, trial shows.
Find out more in The Lancet: spkl.io/60137TUFS #EANO2026
Maarten Lambrecht retweeted
Cell by cell, we shall unravel the contribution of components in patients with #HCC treated with atezo/bev… journal-of-hepatology.eu/art…
Maarten Lambrecht retweeted
Tour de force presentation by my former mentor @michelle_monje for the Abhijit Guha Award and Lecture! #SNO2024 #cancerneuroscience
Maarten Lambrecht retweeted
Brain network topology and its cognitive impact in adult glioma survivors, from @LaurienDeRoeck, @mlambr1, @CharlotteSleurs, @treanus, Jeroen Blommaert, and Patrick Dupont
nature.com/articles/s41598-0…
Maarten Lambrecht retweeted
📢 our latest research published in @Nature Sci Rep 🧠
rdcu.be/dJR8B
Our study reveals how structural brain network metrics are altered in glioma survivors and how these changes are linked to cognitive functions.
@mlambr1 @CharlotteSleurs @treanus
Maarten Lambrecht retweeted
What a great day at @ESTRO_RT!
An honor to present our results on the role of structural hubs in cognition and the association with RT dose 🧠
@FWOVlaanderen @gminniti2012
#radonc #connectome
Maarten Lambrecht retweeted
Donal Hollywood award winner at #ESTRO24
@piet_ost for the STORM trial
Congrats to @ZilliThomas and all contributors 👏
Maarten Lambrecht retweeted
New study🚨Out on @NatureComms unveils #HIFI, a groundbreaking spatial proteomic technique🧬, shedding light on diverse responses to radiation therapy☢️ in brain tumors
✅#glioblastoma 🧠undergoes significant spatial reorganization post-treatment, contrasting with brain metastasis.
nature.com/articles/s41467-0…
@DrSpencerWatson, @BenoitDuc2, @ZiqiKang2000, @NilsEling, @massara_matteo, @jeanhausser & @Johanna_A_Joyce
#OncoAlertAF
@nataliagandur @acampsmalea @MartaPerachino @heinrich_kat @BiagioRicciutMD @DenizCanGuven1
@yekeduz_emre @HHorinouchi @FadiHaddad_MD
@Dr_Ivanoncologo @Abdallah81MD @FernandoOnco
@ElisaAgostinett @dr_yakupergun @to_be_elizabeth
Maarten Lambrecht retweeted
Replying to @drdavidpalma
Adding to the congratulory comments @drdavidpalma. Your leadership and insight in this trial and space is tremendous.
Looking forward to seeing results from this Herculean effort. – at Rancho Santa Margarita, CA
Maarten Lambrecht retweeted
Oh well. Case closed. 😂
@toddscarbrough
Pencil beam scanning proton therapy for pregnant patients with brain and head and neck cancers
Link at: redjournal.org/article/S0360…
37%Yes, this is the new SOC
13%No, it's retro dosimetry
32%I do not discuss protons
19%Why radiate this person
63 votes • Final results Maarten Lambrecht retweeted
#ASTRO2023
Assessment of Precision RT in Early NSCLC and ILD (ASPIRE-ILD) presented by @drdavidpalma
👉 OS at 1-year 78.9%, median OS 25 months
👉 AE event: grade 3 n=4 (10%), grade 4 n=0, grade 5 n=3 (7.7%)
👍 Primary endpoint met, SBRT valid option in overall high-risk pts
Maarten Lambrecht retweeted
#ASTRO2023
High Dose Hyperfractionated Thoracic RT vs. Standard Dose for LS SCLC: Randomized Phase 3 Trial
45Gy in 30 FX vs 54Gy in 30FX
👉 Substantial difference in OS, smaller but significant in PFS
👉 Similar toxicity
❓ Difference in effect size OS vs PFS
❓ Pt selection
Maarten Lambrecht retweeted
In UZ Leuven werd voor het eerst een patiënt op het hart bestraald om levensbedreigende ritmestoornissen te verhelpen. Prof. @EctorJoris: "De samenwerking tussen cardiologen en radiotherapeuten biedt onze patiënten een bijkomende behandelingsoptie."
👉 https://teapaw.org/t.co/jN8pr9bhD0
Maarten Lambrecht retweeted
Single fraction 8Gy vs SBRT 20Gy for painful bone mets, n=126, mostly non-spine #ESTRO23
Complete pain response at 1 mo primary endpoint
👉 no difference at 1 mo
👉 improved in per protocol analysis after 3mo
👉 no increased toxicity
PATIENT SELECTION IS KEY




































